Around the Region
Alnylam, Genzyme form alliance
Alnylam Pharmaceuticals Inc. and Genzyme, both of Cambridge, said Monday that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis, or ATTR, in Japan and other Asia-Pacific countries. Under the terms of the agreement that also includes development milestone payments and tiered royalties, Genzyme will make an upfront cash payment of $22.5 million to Alnylam. ATTR is a rare hereditary disease that damages the nervous system and heart, resulting in a life expectancy of five to 15 years.